Skip to main content

Table 1 Baseline characteristics

From: Acute reverse annular remodeling during MitraClip® therapy predicts improved clinical outcome in heart failure patients: a 3D echocardiography study

 

All patients

High Responder

Low Responder

p

Age (yrs ± SD)

70 ± 11

67 ± 25

72 ± 11

0.15

Male n (%)

29 (64)

15 (75)

14 (56)

0.19

BMI (kg/m2 ± SD)

27 ± 5

27 ± 5

27 ± 5

0.69

Grade of MR n (%)

 

0.86

 4+

33 (73)

14 (70)

19 (76)

 

 3+

5 (11)

4 (20)

1 (4)

 

 2+

7 (16)

2 (10)

5 (20)

 

NYHA n (%)

0.06

 IV

8 (18)

4 (20)

4 (16)

 

 III–IV

11 (24)

8 (40)

3 (12)

 

 III

15 (33)

5 (25)

10 (40)

 

 II–III

8 (18)

3 (15)

5 (20)

 

 II

3 (7)

0

3 (12)

 

Previous interventions n (%)

 CABG or PCI

12 (27)

5 (25)

7 (28)

0.82

 Valve surgery

4 (9)

1 (5)

3 (12)

0.42

 ICD

13 (29)

8 (40)

5 (20)

0.15

 CRT

9 (20)

3 (15)

6 (24)

0.46

Comorbidities n (%)

 AF

30 (67)

9 (45)

21 (84)

0.005

 SR

21 (47)

12 (6)

9 (36)

0.11

 CAD

29 (64)

11 (55)

18 (72)

0.25

 Previous MI

15 (33)

5 25)

10 (40)

0.30

 COPD

8 (18)

5 (25)

3 (12)

0.27

 pHTN

29 (64)

14 (70)

15 (60)

0.51

 Logistic EuroSCORE (% ± SD)

17 ± 17 (6–21)

16 ± 17

133 ± 17 (6–19)

0.84

Medication n (%)

 ACE inhibitors/ARB

29 (64)

13 (65)

16 (64)

0.95

 AT1-antagonists

6 (13)

4 (20)

2 (8)

0.25

 Beta-blockers

41 (91)

18 (90)

23 (92)

0.82

 Loop diuretics

36 (80)

16 (80)

20 (80)

1

 Aldosterone antagonists

22 (49)

12 (60)

10 (40)

0.19

  1. AF atrial fibrillation, BMI Body Mass Index; CABG, coronary artery bypass graft, CAD coronar artery disease, COPD chronic obstructive pulmonary disease, CRT cardiac resynchronization therapy, ICD implantable cardioverter-defibrillator, MI myocardial infarction, MR mitral regurgitation, NYHA New York Heart Association, PCI percutaneous coronary intervention, pHTN pulmonary hypertension, SR sinus rhythm